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I.

INTRODUCTION

Myriad Genetics, Inc. (Myriad), a young 1 genetics
company, specializes in linking human genes to diseases and
establishing the likelihood of a person expressing 2 a gene
developing those diseases. 3 Myriad’s profitable 4 business of
testing customers for diseases linked with these genes has
rested upon Myriad’s ability to monopolize the testing market
by patenting the discovered genes and the testing process.
Between 1997 and 2000, Myriad was issued seven patents
related to the BRCA1 and BRCA2 genes. 5 These genes, due to
Myriad’s research, have been strongly linked to susceptibility
to hereditary breast cancer. 6 Myriad’s seven patents together

© 2011 Peter Edwards.
* University of Minnesota Law School J.D. Candidate, 2012.
1. Founded in May, 1991. Myriad Genetics — About, MYRIAD GENETICS
AND LAB., http://www.myriad.com/about/ (last visited Nov. 24, 2010).
2. In biological terms, a person is said to express a gene when that gene
leads to distinguishable traits in that person. SOLOMON, ET AL., BIOLOGY 261
(Nedah Rose et al. eds., 6th ed. 2002).
3. Id.
4. MYRIAD GENETICS, 2010 ANNUAL SHAREHOLDER REPORT 2 (Sept. 21,
2010).
5. U.S. Patent No. 5,693,473 (filed June 7, 1995); U.S. Patent No.
5,709,999 (filed June 7, 1995); U.S. Patent No. 5,710,001 (filed June 7, 1995);
U.S. Patent No. 5,747,282 (filed June 7, 1995); U.S. Patent No. 5,753,441 (filed
Jan. 5, 1996); U.S. Patent No. 5,837,492 (filed Apr. 29, 1996); U.S. Patent No.
6,033,857 (filed Mar. 20, 1998).
6. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office
(Myriad), 702 F. Supp. 2d 181, 185 (S.D.N.Y. 2010).
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give Myriad a monopoly on any research and testing related to
these genes. 7 Without competition, Myriad has the ability to
control the costs of all such tests, potentially driving the cost
higher than some patients can afford. 8 In May 2009, a
complaint against the United States Patent and Trademark
Office (USPTO) and Myriad was filed in the United States
District Court for the Southern District of New York by, among
others, the Association for Molecular Pathology. 9 In the
resulting case, Association for Molecular Pathology v. United
States Trademark Office and Myriad Genetics (“Myriad”),
plaintiffs attempted to invalidate Myriad’s seven patents, 10
which would effectively terminate Myriad’s monopoly rights on
testing related to the BRCA1/BRCA2 genes. The district court
agreed with plaintiffs that neither the genes nor the testing
methods were patent eligible and invalidated all seven
patents. 11 Myriad appealed to the Court of Appeals for the
Federal Circuit on June 16, 2010. 12 The arguments in the
Myriad case surrounding these patents have hurled genetic
diagnosis to the forefront of intellectual property law and
medicine.
Genetic research, treatment, and diagnostic methods are
growing extraordinarily important as medicine evolves. This
has led to a shift in patenting biotechnology that Congress
could not have foreseen when last amending the Patent Act in
1952. 13 Without incentives to develop medical innovations,
private biotech companies will likely cease much of the
research that results in new diagnostic tests, treatments, and
cures for diseases such as breast cancer. The extent to which
patent law should incentivize this research at the expense of
innovations immediately being placed in the public domain is
an issue central to the Myriad case.
7. Id. at 212–213.
8. Id. at 203.
9. Id. at 186.
10. Id. at 184.
11. Id. at 183.
12. Myriad Defendant’s Notice of Appeal at 1, Ass’n for Molecular
Pathology v. Myriad Genetics Inc., No. 2010-1406 (Fed. Cir. Oct. 22, 2010).
13. The Patent Act of 1952 was the last comprehensive amendment to 35
U.S.C. § 100 (1952). Since then Congress has found it necessary to update the
Patent Act to keep up with the developing field of biotechnology. E.g. 35 U.S.C.
§ 103(b) (1995) (establishing special rules for determining obviousness for
biotechnological process patents).
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The goal of this Comment is to explain the policy concerns
at issue in Myriad and relate them to the options available to
the Court of Appeals for the Federal Circuit in light of the
current state of patent law. The Background section provides
information on the relevant medical, biological, and legal
issues. The Case Summary section describes the facts of
Myriad and the district court’s analysis and ruling. The
Analysis section critiques the district court’s analysis, the
analysis of the main and other interested parties, and suggests
resolutions of all issues faced by the court. This Comment
concludes that both genes as compositions of matter, and
diagnostic testing methods utilizing those genes, are patent
eligible, but that Congress must clarify patent law’s stance on
the issues before further controversy arises.
II. BACKGROUND
A. THE IMPACT OF CANCER
The cost of treating and researching cancer are powerful
influences on our economy. In 2005, Medicare paid
approximately four billion dollars to oncologists for drugs, and
approximately
seven
hundred
million
dollars
for
chemotherapy. 14 Notwithstanding the significant investment in
fighting cancer, it remains tremendously deadly, requiring
continued investment. By 2007, cancer had become the second
highest cause of death in the United States. 15 Further, between
1998 and 2007, total U.S. incidences of cancer had dropped by
only 0.9 percent, 16 and grew by 1.9 percent in people above
sixty-five between 1950 and 2007. 17 On average, the chance of
14. Letter from Laura A. Dummit, Dir., Health Care—Medicare Payment
Issues to The Honorable Joe Barton, Chairman of the Comm. on Energy and
Commerce, House of Representatives 12, 14 (Dec. 1, 2004) (on file with
author). These figures include, presumptively, fees for drugs and oncologist
visits.
15. NAT’L CANCER INST., SURVEILLANCE EPIDEMIOLOGY AND END
RESULTS, SEER CANCER STATISTICS REVIEW 1975–2007: LEADING CAUSES OF
DEATH
IN
U.S.,
1975
VS.
2007
(Nov.
2009),
available
at
http://seer.cancer.gov/csr/1975_2007/results_merged/topic_lead_cod.pdf.
16. NAT’L CANCER INST., SURVEILLANCE EPIDEMIOLOGY AND END
RESULTS, SEER CANCER STATISTICS REVIEW 1975–2007: SEER INCIDENCE
AND U.S. MORTALITY TRENDS BY PRIMARY CANCER SITE AND SEX 1 (Nov.
2009),
available
at
http://seer.cancer.gov/csr/1975_2007/results_single/sect_01_table.07_2pgs.pdf.
17. NAT’L CANCER INST., SURVEILLANCE EPIDEMIOLOGY AND END
RESULTS, SEER CANCER STATISTICS REVIEW 1975–2007: 58-YEAR TRENDS IN
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dying younger than the average life expectancy increases by
forty-four percent once cancer is contracted. 18 Estimates
indicate that a person living in the United States in 2007 had a
more than twenty percent risk of dying of cancer. 19
Breast cancer makes up a large portion of cancer
incidences. Malignant breast cancer alone is the second most
commonly diagnosed type of cancer, and malignant and in situ
breast cancer combined are the most frequently diagnosed. 20
More deaths result from breast cancer than any other cancer
except lung cancer, 21 even though breast cancer has an 89
percent survival rate. 22 Breast cancer is the most common
cancer in younger persons 23 and disproportionally affects
women. 24 It is understandable that litigation concerning this
disease would have an effect on a significant proportion of the
United States population.
B. THE BIOLOGY OF INHERITANCE
Given the technical nature of the dispute between the
U.S.
CANCER
DEATH
RATES
1
(Nov.
2009),
available
at
http://seer.cancer.gov/csr/1975_2007/results_single/sect_01_table.02.pdf.
18. NAT’L CANCER INST., SURVEILLANCE EPIDEMIOLOGY AND END
RESULTS, SEER CANCER STATISTICS REVIEW 1975–2007: AGE-ADJUSTED
SEER INCIDENCE AND U.S. DEATH RATES AND 5-YEAR RELATIVE SURVIVAL
(PERCENT) 1 (Nov. 2009) [hereinafter AGE-ADJUSTED SEER INCIDENCE],
available
at
http://seer.cancer.gov/csr/1975_2007/results_single/sect_01_table.04_2pgs.pdf.
19. NAT’L CANCER INST., SURVEILLANCE EPIDEMIOLOGY AND END
RESULTS, SEER CANCER STATISTICS REVIEW 1975–2007: LIFETIME RISK
(PERCENT) OF DYING FROM CANCER BY SITE AND RACE/ETHNICITY 1 (Nov.
2009),
available
at
http://seer.cancer.gov/csr/1975_2007/results_single/sect_01_table.04_2pgs.pdf.
20. NAT’L CANCER INST., SURVEILLANCE EPIDEMIOLOGY AND END
RESULTS, SEER CANCER STATISTICS REVIEW 1975–2007: LIFETIME RISK
(PERCENT) OF BEING DIAGNOSED WITH CANCER BY SITE AND RACE/ETHNICITY
1 (Nov. 2009) [hereinafter RISK OF BEING DIAGNOSED], available at
http://seer.cancer.gov/csr/1975_2007/results_single/sect_01_table.14_2pgs.pdf.
21. Id.
22. AGE-ADJUSTED SEER INCIDENCE, supra note 18. These unexpected
numbers illustrate the immense number of breast cancer incidences among
other, deadlier cancers.
23. NAT’L CANCER INST., SURVEILLANCE EPIDEMIOLOGY AND END
RESULTS, SEER CANCER STATISTICS REVIEW 1975–2007: U.S. PREVALENCE
COUNTS, INVASIVE CANCERS ONLY, JANUARY 1, 2007, at 4 (Nov. 2009),
available
at
http://seer.cancer.gov/csr/1975_2007/results_single/sect_01_table.21_2pgs.pdf.
24. RISK OF BEING DIAGNOSED, supra note 20.

2011]

MEDICINE AND PATENT LAW

815

parties, a basic understanding of genetic inheritance is
required before analyzing the issues. Biologically, inheritance
is a function of person’s DNA, 25 which is handed down from
previous generations. 26 DNA is composed of a long strand of
sequential bases: adenine, guanine, thymine, and cytosine. 27
These bases are small, ring or figure-eight shaped molecules
made up of 15 assorted carbon, nitrogen, oxygen and hydrogen
atoms. 28 The specific sequence of these bases is passed down to
a person from that person’s parental generation; it determines
development by dictating which proteins that person will
produce. 29 It follows, then, that determining the sequence of
bases in a person’s DNA will uncover the genetic traits that
person has inherited.
However, much of a person’s DNA is not translated into
proteins; this DNA is termed non-coding. 30 Therefore,
determining a person’s genes is a more effective method of
determining a person’s inherited traits. 31 Genes are the
portions of a person’s DNA that are eventually expressed, i.e.
translated into proteins. 32 The genes of a person’s DNA are
“read” to form RNA by a process known as transcription. 33 The
type of RNA that carries information from genes is known as
messenger RNA (mRNA). 34 mRNA is composed of the base
sequences of a particular gene, but can itself be broken down
into introns and exons. 35 Introns are noncoding sequences of
mRNA; exons eventually dictate what proteins an organism
will produce and thus how that organism will develop. 36 This
occurs in a process called translation, during which the exons of
a sequence of mRNA are “read” to determine the sequence in
which to assemble amino acids to form a protein. 37 However,
before this occurs, the mRNA formed in transcription must be

25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.

SOLOMON, supra note 2 at 244.
Id. at 217.
Id. at 247.
Id. at 249.
Id. at 261.
Id. at 264, 266.
See id. at 218.
Id. at 278.
Id. at 265.
Id. at 264.
Id. at 275.
Id.
Id.
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processed, at which point the introns are removed. 38 The
remaining exons are translated into specific proteins, 39 and
those specific proteins determine how an organism will
develop. 40 Therefore, by removing the regions of a person’s
DNA that are not genes and the introns from the remaining
genes by simulating transcription and mRNA processing, one
can discover, from the exons that remain, the exact proteins
that person will produce. Further, by running the processed
mRNA through a reaction known as reverse transcription, it is
possible to produce complementary DNA (cDNA), a stable
template of the exons that exhibit those proteins. 41
If a person inherits DNA that has been changed, or
mutated, that change may be reflected in that person’s DNA if
the mutation occurs on an exon. 42 This will change a person’s
physical development, which could have disastrous results. 43
Most mutations will not be expressed because they occur in the
non-coding portion of a person’s DNA that are either (1) not
transcribed to RNA, or (2) occur in the introns, and thus are not
translated into proteins. 44 However, mutations such those on
the BRCA1 gene and the BRCA2 gene have effects that are not
easily noticed. The BRCA1 and BRCA2 genes have been linked
to susceptibility to breast cancer, 45 and therefore changes in a
person’s development as a result of a BRCA1 or BRCA2
mutation could significantly increase a person’s likelihood of
developing the disease. Furthermore, these mutations may be
passed down to future generations, creating the same increased
likelihood in a person’s children. 46
DNA is reproduced in an organism, but geneticists are also
able to produce it in greater volume using the polymerase chain
reaction (PCR). 47 In PCR, double-stranded DNA 48 is separated

38. Id.
39. Id.
40. Id.
41. Id. at 306.
42. Id. at 279.
43. Id.
44. See id. at 264, 266.
45. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office
(Myriad), 702 F. Supp. 2d 181, 185 (S.D.N.Y. 2010).
46. See SOLOMON ET AL., supra note 2, at 217.
47. SOLOMON ET AL., supra note 2, at 307.
48. DNA is naturally found in a double helix form. See id. at 247.
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into two single strands, at which point primers, 49 DNA bases,
and replication enzymes 50 are added to the DNA mixture. 51
These components combine to duplicate each strand of DNA,
doubling the amount of DNA in the mixture. 52 With proper
enzymes and an adequate supply of components, this process
can be repeated indefinitely, each time doubling the amount of
DNA. 53
It follows that, because mutations are changes in the
sequences of bases in a person’s DNA, a person with a mutated
gene will have a different DNA sequence than a person with
the “normal” or “baseline” gene. To determine the sequence of a
baseline gene, geneticists perform a special method of PCR
using both regular bases and dideoxynucleotides, synthetic
bases that attach to a single strand of DNA just as to an
ordinary base, but that stop replication once attached to the
DNA strand. 54 With enough starting strands and enough bases,
there will be a strand produced with the dideoxynucleotide at
every position of the sequence. 55 The segments are organized
from shortest to longest, and the last base of each segment
length are recorded. 56 For a simplified example, if a strand had
the sequence ACGT, the process would result in four groups of
segments. By counting the groups of segments, it would become
clear that the total segment length is four bases. Segments in
the first group would be one base long (A) with the As
radiated. 57 Segments in the second group would be two bases

49. A primer is a short sequence of RNA bases that attach to a strand of
DNA to mark the start point of replication. They are replaced by DNA bases
shortly. See id. at 253.
50. There are several enzymes involved in DNA replication, specific
knowledge of which is not necessary here. See generally id. at 252–53.
51. Id. at 307.
52. Id.
53. Id.
54. Id. at 309.
55. Therefore, if the target sequence was one-hundred bases long, the
result would be at least one strand produced corresponding to each of the
hundred positions. Id.
56. Ordering by segment length and recording of terminal bases is
performed using gel electrophoresis and autoradiography respectively. Gel
electrophoresis and autoradiography are processes by which very small
compounds can be separated and identified. No further understanding is
relevant here. Id. at 308–09.
57. Autoradiography radiates the end bases of a strand, making the
identity of the base at the end of the strand in each group easily discernable.
Id.
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long (AC) with the Cs radiated. Segments in the third group
would be three bases long (ACG) with the Gs radiated, and so
on. When this process is completed, the total segment length is
known, the base for each position of the segment is discovered,
and thus the sequence of the entire segment is known. 58
Fortunately, PCR (and thus, dideoxynucleotide PCR) can
be performed on only the target sequence to be replicated, so
long as the primers (short segments at the beginning of a gene
of recognized base pattern) for the sequence are known. 59 Thus,
if geneticists are able to locate the gene they wish to sequence
and/or replicate, they will be able to target that gene
specifically for sequencing and/or replication. 60 Therefore, if the
sequence of a baseline gene is known, a specific person’s gene
sequence can be compared to that baseline gene sequence to
identify any points at which the bases differ. 61
C. LEGAL PRECEDENT OF PATENTING GENES
The precise protection rights afforded to a holder of a
patent of a human gene are hard to determine. For example,
the USPTO claims that while genes are patentable, the
sequences themselves and the underlying genetic information
are not. 62 It is not clear what the researcher is patenting in a
gene, however, if not genetic information. The USPTO’s
explanation of a patent holder’s rights do not provide much
clarification. The USPTO claims that the patent holder has the
right to exclude all others from any use of that gene, 63 but also
that the patent holder must promote discovery of other uses of
the gene by other researchers. 64 These other uses, according to
the USPTO, would be patentable by the discoverers of those
uses as an improvement on an existing invention. 65 The
USPTO does not explain how non-patent-holding researchers
would be able to discover new uses for a gene when the patent

58. Id. at 309.
59. Id. at 307.
60. Id.
61. These points of differing bases would represent mutations in the
person’s gene.
62. U.S. PATENT & TRADEMARK OFFICE, DEP’T OF COMMERCE, RIN 0651AB09, UTILITY EXAMINATION GUIDELINES 1093 (2001).
63. Id. at 1095.
64. Id. at 1094.
65. Id. at 1095.
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holder has a right to ban all research on the gene. 66
Congress has the power to “promote the Progress of
Science and useful Arts, by securing for limited Times to
Authors and Inventors the exclusive Right to their respective
Writings and Discoveries.” 67 Pursuant to these objectives,
Congress passed the Patent Act of 1836, which established the
USPTO as the initial deciding body for all patent
determinations, established a numerical system to track
patents, and established the patent eligibility criteria. 68 From
that point on, “any person or persons having discovered or
invented any new and useful art, machine, manufacture, or
composition of matter, or any new and useful improvement on
any art, machine, manufacture, or composition of matter . . .”
could be granted patent protection. 69 In order to receive a
patent, an invention or discovery must be determined to be (1)
patent eligible, and (2) patentable. 70 Whether an invention is
eligible for a patent is determined by the patent protection
assigned to that type of invention. 71 Whether an invention is
patentable, on the other hand, depends on the specific
properties and history of that particular invention, not the field
in which the invention falls. 72 Therefore, for an invention to be
patented, it must (1) fall into a class of inventions to which
patent protection can be assigned, and (2) comply with
statutory provisions regarding the properties of that particular

66. It is worthy of note that § 271 of the Patent Act provides an
experimental use exception which protects researchers of patented
compounds, but only if they begin their research with a reasonable belief that
the research, if successful, will result in information relevant to a new drug
application to the Food and Drug Administration. 35 U.S.C. § 271 (2010);
Merck KGAA v. Integra Lifesciences I, Ltd., 545 U.S. 193, 208 (2005). While
this exception is broad, the Court held that a research must have an intended
physiological effect, and a reason to believe the research would produce that
effect. General exploratory research, therefore, is not protected. Merck, 545
U.S. at 205–06.
67. U.S. CONST. art. I § 8, cl. 8.
68. Patent Act of 1836, 5 Stat. 117, (a), § 5–6 (1836).
69. Patent Act of 1836, 5 Stat. 117, §6 (1836); 35 U.S.C. § 100 (2006).
Patent protection did not originate with the establishment of the USPTO, nor
with an act of Congress. Even before the Constitution was ratified, state
patent protection was available. Sears, Roebuck & Co. v. Stiffel Co., 376 U.S.
225, 228 (1964). Additionally, some federal patent protection existed after
1790. Id. at 229.
70. 35 U.S.C. § 101–02 (2006).
71. See 35 U.S.C. § 101 (2006).
72. See 35 U.S.C. § 102 (2006).
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invention. 73 The invention must be found by the examiner to be
novel 74 and non-obvious 75 and the inventor must be able to
show that he or she is the actual inventor. 76
When the Patent Act was passed, the phrase “new and
useful art” was written to refer to a method by which
something was done. It now has been replaced by the phrase
“new and useful process” to reflect this meaning. 77 Therefore,
according to the Patent Act, an inventor can patent both a
compound (a composition of matter) and the process by which
that compound is made. Further, in certain biotechnical fields,
a process and a composition of matter that may otherwise have
been found to be too obvious to be patentable may still be
patentable if, for example, the process and the composition are
claimed in the same application. 78
Patenting chemical compounds is far from a matter of first
impression for the USPTO or the courts. 79 Indeed, even
patenting chemical compounds that were purified but are
otherwise unchanged from the compound found in nature is not
a new subject. 80 Since these early patents, many patents have
been issued for chemical compounds. 81 These compounds were
often extractions from living organisms, whether plant or
animal. 82 This eventually led to patenting the organisms
themselves: in May of 1930, Congress passed the Plant Patent
Act, enabling discoverers of new plants to achieve patent
protection for their discoveries, provided they had asexually
reproduced the plants. 83 This was a milestone for patent law,
73. See 35 U.S.C. §§ 101–02 (2006).
74. In order to be novel, the process or composition of matter claimed
must not be publicly known. See 35 U.S.C. § 102 (2006).
75. To be non-obvious, the necessary innovation from prior inventions to
arrive at the new invention must not be clear to a person well versed in the
field from which the invention derives. 35 U.S.C. § 103(a) (2006).
76. 35 U.S.C. § 102(f) (2006).
77. Patent Act of 1836, 5 Stat. 117, § 6 (1836); 35 U.S.C. § 101 (2006).
78. 35 U.S.C. § 103(b)(1)(A) (2006).
79. E.g., U.S. Patent No. 141,072 (filed May 9, 1873).
80. E.g., Parke-Davis & Co v. H.K. Mulford & Co., 196 F. 496, 496 (2d Cir.
1912) (considering whether purified adrenaline, having been previously
discovered in animal suprarenal tissue, was patent eligible).
81. See, e.g., U.S. Patent No. 2,200,004 (filed Nov. 12, 1988); U.S. Patent
No. 2,400,006 (filed Mar. 3, 1945).
82. See, e.g., Merck v. Mathieson, 253 F.2d 156, 164 (2d Cir. 1958); ParkeDavis, 196 F. at 496.
83. Plant Patent Act of 1930, Pub. L. No. 245 (1930).
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as it allowed inventors to patent living things that may have
been, in a sense, invented by nature. 84 In 1954, Congress
amended the Plant Patent Act to separate the plant patent
provisions from the original patent provisions and added more
stringent requirements that the plants be new and distinct. 85
In 1970 Congress passed the Plant Variety Protection Act,
which entrusted the Secretary of Agriculture to ensure plants
are examined for protectability 86 and established a plant
variety protection board to oversee appeals of an examiner’s
decision not to protect a plant. 87 Further, the Act extended the
patent eligibility to sexually-reproducing plants, eliminating
the requirement that inventors must have asexually
reproduced the plant. 88
The USPTO and Supreme Court have since extended
patent eligibility to non-plant organisms, including bacteria
and the process of producing bacteria. 89 However, when the
“invention” for which an inventor is seeking protection is an
organism or group of organisms, an exception to patent
eligibility may apply, and the inventor must not simply be
attempting to patent a pure product of nature. 90 To overcome
this presumption, an inventor must demonstrate that the
product of nature has become a new and distinctive article with
new characteristics and/or a new use. 91 Further, the
presumption cannot be overcome by combining different groups
of organisms, unlike patents on non-natural inventions. 92
There is some suggestion that this rule applies to purifications
of substances found in nature as well. 93
84. A plant that is created artificially and is not known in nature may be
eligible for patent. See id. However, a patented plant may still exist in nature,
albeit undiscovered.
85. Pub. L. No. 775, 68 Stat. 1190 (1954).
86. Plant Variety Protection Act, Pub. L. No. 577, 84 Stat. 1542 (codified
at 7 U.S.C. §§ 2321–72, 2401–504, 2531–83).
87. Pub. L. 91–577, § 7, 84 Stat. 1543 (1970) (codified at 7 U.S.C. §
2327(b)(2)).
88. Pub. L. 91–577, § 42, 84 Stat. 1547 (1970) (codified at 7 U.S.C. § 2402).
89. Diamond v. Chakrabarty, 447 U.S. 303, 310–11 (1980). It is worthy of
note that the Plant Variety Protection Act specifically excluded bacteria from
patent eligibility. Id.
90. Funk Bros. Seed Co. v. Kalo Inoculant Co. (Funk Bros.), 333 U.S. 127,
130 (1948).
91. Anheuser-Busch Brewing Ass’n v. United States, 207 U.S. 556, 562
(1908).
92. Funk Bros., 333 U.S. at 131–32.
93. See In re Merz, 97 F.2d 599, 601 (C.C.P.A. 1938)
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This same concept has been applied to method/process
patents as well. A natural process or law of nature is patent
eligible, but only if, when the process is considered as a whole,
the patent is attempting to gain protection for the application
of the law, rather than the law itself. 94 When the formula is
applied to perform a function that patent law was developed to
protect, the process should be given more leniency. 95 This
factor has led to some confusion in differentiating between
patenting the application of a law of nature and patenting a
fleshed-out abstract idea. 96
To summarize, the machine-or-transformation test
required that all method/process patent eligible inventions
must either be applied as some part of a machine or must be
applied in a way that transforms something. 97 But the
machine-or-transformation test has been rejected as the sole
test to determine patent eligibility of a process; instead, the
proper test is whether the process amounts to an abstract
idea. 98 Unfortunately, no explicit definition or test for what
constitutes an abstract idea has been provided. 99
Yet another layer of uncertainty has recently arisen in
patent law: patenting human genes. Whether human genes fall
into the category of a simple product of nature 100 or something
sufficiently transformed to be patent eligible 101 is unclear. In
its 2001 Utility Examination Guidelines, the USPTO
consistently confirmed that genes were patent eligible subject
matter. 102 The USPTO suggests that a strand of DNA will be
94. Diamond v. Diehr, 450 U.S. 175, 187 (1981).
95. Id. at 192.
96. Compare Diehr, 450 U.S. at 192 (holding that an application for a
mathematical formula to an end in furtherance of the purposes of patent law
is patent eligible) and AT&T v. Excel Corp. 172 F.3d 1352, 1357 (Fed. Cir.
1999) (holding that, for patent eligibility, a mathematical formula must be
applied in a manner that creates a tangible result) with Parker v. Flook, 437
U.S. 584, 595 n.18 (suggesting that the application of an improved method of
calculation, even when supporting a specific end use, is not patent eligible).
97. E.g., In re Bilski, 545 F.3d 943, 956 (Fed. Cir. 2008).
98. Bilski v. Kappos, 130 S. Ct. 3218, 3231 (2010).
99. Id.
100. See, e.g., American Fruit Growers v. Brogdex Co., 283 U.S. 1, 11–12
(1931) (finding a process not patentable because it was a simple product of
nature).
101. Diamond v. Chakrabarty, 447 U.S. 303, 309–10 (1980).
102. UNITED STATES PATENT AND TRADEMARK OFFICE, DEP’T OF
COMMERCE, RIN 0651-AB09, UTILITY EXAMINATION GUIDELINES passim
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patentable when: (1) it has been isolated from its natural
environment, (2) it has been purified, and (3) it meets the
statutory requirements for patentability. 103 The USPTO
emphasizes the nonobviousness and utility requirements of the
patent statute, 104 and also clarifies that isolated genes,
whether excised from a person’s cells or synthesized in a lab,
are patentable because they vary so greatly from their natural
forms. 105
The issue of patenting genes has also been brought to the
Court of Appeals for the Federal Circuit, which has historically
upheld gene patents. In 1995, the court held that a patent on a
gene could not be invalidated solely because the method by
which the gene was sequenced was a commonly exercised
principle. 106 The court was not convinced by the fact that the
method used to discover the gene sequence was “obvious to try”
because one of ordinary skill in the art, when trying the
method, would have very little chance of contemplating the
result. 107 The court delivered a similar decision in 1993, which
clarified that the obviousness of the method by which a patent
holder discovered the compositions of DNA was not at issue in
the case. 108 The patent holder did not claim the method of
discovery, but only the compositions, and because the
compositions were not at all obvious, the patent could not be
invalidated on grounds of obviousness. 109 However, in 2007 the
Supreme Court questioned these cases, and, in reinstating the
obvious-to-try analysis, held that an invention will be
considered obvious to try if “there is a design need or market
pressure to solve a problem and there are a finite number of
identified, predictable solutions.” 110 The Court concluded that
an invention found obvious to try can preclude patentability for
§ 103 purposes. 111 The Federal Circuit embraced the obviousto-try test in the recent genetic case, In re Kubin, holding that a

(2001).
103. Id. at 1093.
104. Id. at 1093–95.
105. Id. at 1093.
106. In re Deuel, 51 F.3d 1552, 1557–59 (Fed. Cir. 1995).
107. Id.
108. In re Bell, 991 F.2d 781, 785 (Fed. Cir. 1993).
109. Id.
110. KSR Intern. Co. v. Teleflex Inc., 550 U.S. 398, 421 (2007).
111. See id. (suggesting that finding a combination of elements making up
an invention obvious-to-try may show that it is obvious under the statute).
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finding of obvious-to-try will equal a finding of obviousness in
almost all cases. 112 While the specific question with which the
court is faced in Myriad may be one of first impression,
patenting of genes and even of life is far from a new subject.
D. COMMENT PREVIEW
The purpose of this Comment is to explore the underlying
issues of the suit between the Association for Molecular
Pathology and Myriad Genetics, and to determine the proper
course of action for the Court of Appeals for the Federal Circuit
and the Supreme Court, should the case continue to that level.
Analysis of such a complex issue will require an incorporation
of public policy and legal issues. To that end, this Comment will
first present in greater detail the disputed patents and issues of
Myriad at its current state. The next section will examine the
public policy ramifications of invalidating or validating the
seven patents at issue, including a consideration of the effects
on all present and potential future genetic patents. This
Comment will then analyze the legal arguments and
consequences of each possible decision. Finally, this Comment
will conclude with a summary of the analysis section and a
final suggestion on the overall best course of action.
III. CASE DESCRIPTION
In 1997, Myriad was granted a patent on a human gene,
BRCA1, which directs the development of a protein in both men
and women that is linked to hereditary breast cancer. 113
Between 1998 and 2000 Myriad was granted six more
patents 114 relating to both the BRCA1 and BRCA2 genes and
the methods of using them to diagnose hereditary breast
cancer. 115 Myriad has been the sole provider offering the
112. In re Kubin, 561 F.3d 1351, 1359 (Fed. Cir. 2009) (holding that if an
inventor merely guesses at the proper use of a large pool of prior art by
“throw[ing] metaphorical darts at a board filled with prior art possibilities,” or
if all that was obvious to try was “to explore a new technology or general
approach” and “prior art gave only general guidance,” being obvious to try
would not lead to a finding of obviousness. See id. (quoting In re O’Farrell, 853
F.2d 894, 903 (Fed. Cir. 1988)).
113. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office
(Myriad), 702 F. Supp. 2d 181, 189, 201 (S.D.N.Y. 2010).
114. The University of Utah Research Foundation is a joint holder of these
patents. Id. at 189–90.
115. Id.
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diagnostic tests ever since, because its patents give it a
monopoly on the underlying methods. Plaintiffs, 116 unhappy
with (1) the costs of Myriad’s diagnostic testing, (2) their
inability to perform competitive diagnostic testing, or (3)
Myriad’s potential ability to prevent outside research on
BRCA1 and BRCA2, brought an action against the USPTO and
Myriad 117 in the United States District Court for the Southern
District of New York to invalidate the patents. The district
court case was heard and decided by Judge Robert Sweet. 118
The plaintiffs moved for summary judgment, arguing that
the disputed claims covered only products of nature, laws of
nature/natural phenomena, and abstract ideas. 119 Myriad
cross-moved for summary judgment, and the USPTO moved for
judgment on the pleadings. 120 The court granted the plaintiffs’
motion against Myriad, granted the USPTO’s motion, and
denied Myriad’s cross-motion. 121
The opinion discussed three accepted exceptions to the
general patentability of new and useful inventions: the law of
nature exception, the physical phenomena exception, and the
abstract idea exception. 122 It then addressed the composition of
matter claims and method claims in turn, citing different
support for patent ineligibility for each category. 123 The opinion
focused on a product of nature exception to the general patent
eligible status given to compositions of matter. 124 This
exception, according to the opinion, establishes that
compositions of matter are not patentable if those compositions
of matter are merely products of nature that have not been
changed to the point of being fundamentally a new product. 125

116. An exhaustive list of all plaintiffs would be, appropriately, exhausting
to list here. Together, there are twenty plaintiffs, encompassing four research
groups, eight doctors and scientists, two health action groups, and six women
diagnosed with breast cancer. Id. at 186–89.
117. The University of Utah Research Foundation was also listed as a
defendant, as it had partial ownership of the patents-in-suit. Id. at 189–90.
118. Id. at 183.
119. Id. at 184.
120. Id. at 184–85.
121. Id. at 238. The claims against the USPTO were dismissed due to the
doctrine of constitutional avoidance. This doctrine will not be discussed by this
Comment.
122. Id. at 219 n. 40.
123. Id. at 220–37.
124. Id. at 222–27.
125. Id. at 222.
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For this exception, the opinion relies on three cases: 126
American Fruit Growers, Inc. v. Brogdex Co., 127 Funk Bros.
Seed Co. v. Kalo Inoculant Co., 128 and Diamond v.
Chakrabarty. 129 This test establishes that an invention may
defeat the product of nature exemption if the invention has
been changed to such an extent as to have a “distinctive name,
character, [and] use” from the product of nature. 130
The opinion concludes that Myriad’s composition of matter
claims do not pass the product of nature test, as the claimed
DNA is not markedly different than the natural DNA. 131 In
arriving at this conclusion, it suggests that DNA should be
judged differently than many chemical compounds because of
the importance of the information-storing capacities of DNA. 132
That the claimed DNA does not contain non-coding regions of
the strand, is not attached to other genes on a chromosome,
and is not located among other components of a cell
environment are irrelevant. That the information encoded
remains unchanged between the claimed DNA and the natural
DNA is enough to show that the claimed DNA is not markedly
different from the natural DNA. 133 The opinion notes that the
claimed DNA would, in fact, be worthless if the information
encoded were not exactly the same as natural DNA. 134 Further,
it suggests that many of Myriad’s claims could be invalidated
because they are broad enough to encompass natural DNA as
well as synthesized DNA, which is, by definition, not markedly
different from a product of nature. 135 Even the claims for
cDNA, it suggests, are not markedly different from products of
nature, because cells have the means to produce cDNA from
native DNA, and therefore cDNA may exist in the cell. 136
Myriad’s method claims are also held to be invalid. 137 The
126.
127.
128.
(1948).
129.
130.
131.
132.
133.
134.
135.
136.
137.

Id. at 222–23.
American Fruit Growers v. Brogdex Co., 283 U.S. 1 (1931).
Funk Bros. Seed Co. v. Kalo Inoculant Co. (Funk Bros.), 333 U.S. 127
Diamond v. Chakrabarty, 447 U.S. 303 (1980).
Myriad, 702 F. Supp. 2d at 223
Id. at 220.
Id. at 228.
Id. at 229.
Id. at 231.
Id. at 230.
Id.
Id. at 232–37.
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finding is based not on any of the three discussed exceptions,
but rather on the “machine or transformation” test articulated
by the Federal Circuit in In re Bilski. 138 According to the
machine or transformation test, a claim for a method is invalid
if it is not connected to a machine, or does not transform an
article. 139 Myriad’s claims do not teach a method that is
connected to a machine and the transformation argued by
Myriad is insufficient. 140 The opinion states that Myriad’s
claims are too broad because they only use general terms such
as “data gathering” and “comparing.” 141 Further, drawing of a
patient’s blood and isolating his or her DNA sample are not
transformative enough because it is simply collecting a sample
and preparing it for data-gathering. 142 The transformation
must be essential to the claimed process, and drawing blood
and isolating the DNA are not the focus of Myriad’s claimed
method—the focus is in comparing the two samples. 143
Comparing the two samples is simply an application of the
scientific method, which is neither transformative nor novel. 144
The court did not address whether the composition-of-matter or
diagnostic-method patents were patentable under § 102 for
novelty and § 103 for nonobviousness. 145
Myriad’s composition-of-matter claims were held to be
patent ineligible because they were products of nature.
Myriad’s method claims were also held to be patent ineligible
because they were not tied to a machine or transformation
process. The district court opinion was filed on March 29, 2010,
invalidating Myriad’s patents. 146 Myriad filed a notice of appeal
to the Court of Appeals for the Federal Circuit on June 16,
2010, seeking reversal of the decision. 147

138. In re Bilski, 545 F.3d 943 (Fed. Cir. 2008), modified, Bilski v. Kappos,
130 S. Ct. 3218, 3226 (2010).
139. Myriad, 702 F. Supp. 2d at 233.
140. Id.
141. Id. at 234, 236.
142. Id. at 236.
143. Id.
144. Id. at 237.
145. Id. at 220 (noting that the sole purpose of the court was to determine
whether Myriad’s inventions fell under the product of nature exception).
146. Id. at 181.
147. Notice of Appeal for Appellant Myriad at 1, Ass’n for Molecular
Pathology v. Myriad Genetics Inc., No. 2010-1406 (Fed. Cir. filed June 16,
2010). The USPTO, on the other hand, did not appeal, as the court dismissed
the claims against it. Myriad, 702 F. Supp. 2d at 237–38.
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IV. ANALYSIS
This section will present precedents of finding gene patents
eligible and explain how the Myriad opinion improperly applied
Chakrabarty, Funk Bros. and the now-questionable In re Bilski
and was therefore insufficient to reverse the USPTO’s decision
and find that genes are patent ineligible. This section will then
explain the need for gene patent eligibility from a public policy
viewpoint. 148 Finally, it will explore the § 102 novelty and § 103
obviousness obstacles genetic diagnostic methods are likely to
face before being granted patent status.
A. MYRIAD’S COMPOSITION-OF-MATTER CLAIMS ARE PATENT
ELIGIBLE
This section will show that the court’s analysis fails to
invalidate Myriad’s composition of matter patents. First,
Myriad’s composition of matter patents do not fall under the
product of nature exception. Second, they are more than
purifications of natural mixtures. Third, Funk Bros., arguably
the opinion’s strongest support, does not apply to this action.
Finally, deference to Congress, the USPTO, and other courts
strongly supports a finding of patent eligibility.
1. The Scope of § 101
Section 101, addressing what inventions are eligible to be
considered for patents, was written to apply broadly. 149 The
1793 Act is said to have been authored by Thomas Jefferson, 150
who instilled in it his belief that “ingenuity should receive a
liberal encouragement.” 151 Though the Act has been amended
148. This Comment approaches legal analysis first, for if patenting genes is
found to be clearly foreclosed by law, public policy is moot. See Dir., Office of
Workers’ Comp. Programs v. Newport News Shipbuilding & Dry Dock Co., 514
U.S. 122, 129 (1995) (holding that, absent clear language in the statute in
question, workers rights could not be brought to court by the secretary of labor
even though public policy greatly favored it); Diamond v. Chakrabarty, 447
U.S. 303, 317–18 (1980) (holding that the court is neither equipped nor
authorized to second-guess Congress’ determinations of patent eligibility
based on public policy concerns).
149. 35 U.S.C. § 101 (2006) (establishing that “any new and useful. . .
composition of matter. . . or any new and useful improvement thereof” may be
patented subject to other restrictions of the act) (emphasis added).
150. Chakrabarty, 447 U.S. at 308–09.
151. Thomas Jefferson in 5 WRITINGS OF THOMAS JEFFERSON 75–76
(Washington ed. 1871).
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multiple times, Jefferson’s broad language has never been
restricted. 152 In fact, accompanying the latest amendment in
the 1952 Act, Congressional committee reports explicitly state
that “anything under the sun that is made by man” qualifies for
patent eligibility under § 101. 153 The courts have concluded
that advanced technologies that Congress would have had no
way of anticipating when the act was written are not patent
ineligible per se. 154 Indeed, the Supreme Court has held that it
cannot read limitations into statutes that were not intended by
Congress. 155 However, the Supreme Court has also cautioned
that courts should use extreme prudence when “expanding”
patent eligibility to those areas. 156 As guidance, the Supreme
Court has established three general exceptions to the
presumption of patent eligibility: laws of nature, physical
phenomena, and abstract ideas. 157
2. The Product-of-Nature Exception is Valid
The Myriad respondents successfully argued that human
genes, when isolated from surrounding DNA and other cellular
components, are not patent eligible because they fall under the
product-of-nature exception. 158 Myriad argues, however, that
this “product of nature’ exception on which the decision relies is
not one of the three exceptions described in Chakrabarty.
Chakrabarty does not mention a “product of nature” exception,
but only “laws of nature.” 159 The Myriad opinion describes the
“product of nature” exception as a general combination of “the
law[] of nature, natural phenomenon, and abstract idea[]”
exceptions cited in Chakrabarty, 160 and one of the examples the
Court used in Chakrabarty to clarify the three exceptions fits
Judge Sweet’s definition of a product of nature. 161 Myriad
152. Chakrabarty, 447 U.S. at 309.
153. S. REP. NO. 82-1979 at 5 (1952). While this statement may be too
overbroad to be read literally, it certainly supports a broad construction o the
act.
154. Chakrabarty, 447 U.S. at 316.
155. United States v. Dubilier Condenser Corp. 289 U.S. 178, 199 (1933).
156. Parker v. Flook, 487 U.S. 584, 596 (1978).
157. Chakrabarty, 447 U.S. at 309.
158. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office
(Myriad), 702 F. Supp. 2d 181, 184, 222, 228 (S.D.N.Y. 2010).
159. 447 U.S. at 309.
160. Myriad, 702 F. Supp. 2d at 220.
161. Chakrabarty describes a hypothetical new mineral discovered in the
earth as patent ineligible under the three exceptions. 447 U.S. at 309.
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argues that the products of nature test improperly limits the
statute beyond congressional intent. 162 Myriad itself admits
that the exceptions set out in Chakrabarty were meant not to
limit the statute but to provide guidance for the “new and
useful” determination of § 101. 163 This type of guidance is
precisely the purpose of the courts. 164 Myriad also suggests
that such a sweeping exception in patent law would frustrate
the patent statute, but does not give support for the district
court or court of appeals to overturn a holding of the Supreme
Court. 165 Myriad has not established that the district court
misunderstood the underlying exceptions expressed by the
Supreme Court in Chakrabarty. Myriad’s argument against
the “product of nature” exception, without more, is merely
semantic.
3. Myriad’s Genes Do Not Fall Under the Product of Nature
Exception.
Myriad’s stronger argument is that which it presented to
the district court: that its patented genes have been sufficiently
altered so as to not fall under any of the three exceptions. 166
Even if natural DNA is generally analogous to a hypothetical—
newly discovered mineral, as described in dicta as patent
ineligible by Chakrabarty 167 —Myriad argues that its claimed
DNA is not specifically analogous, because it is isolated from its
cellular surroundings and is devoid of introns and any DNA
associated proteins, it is purified. 168
The Myriad opinion’s analysis of the exceptions in
Chakrabarty focused on whether Myriad’s claimed DNA meets
“[the] requirement that an invention possesses ‘markedly

162. Brief for the Appellants at 1, Ass’n for Molecular Pathology v. Myriad
Genetics, Inc., No. 2010-1406 (Fed. Cir. filed June 16, 2010).
163. Id. at 33.
164. Cf. Marbury v. Madison, 5 U.S. (1 Cranch) 137, 147 (1803) (holding
that the U.S. Supreme Court has jurisdiction to interpret laws passed by
Congress).
165. Brief for the Appellants, supra note 162 at 46.
166. Myriad, 702 F. Supp. 2d at 224.
167. See supra note 161. This comment, for argument’s sake, will assume
that natural DNA, extracted in a pure chromosomal form, is directly
analogous to the hypothetical mineral described in the Court’s analysis in
Chakrabarty.
168. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office
(Myriad), 702 F. Supp. 2d 181, 224 (S.D.N.Y. 2010).
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different characteristics’ [than the natural analog].” 169 Myriad
argues that Chakrabarty did not establish the “markedly
different characteristics” analysis as a test. 170 Instead, Myriad
suggests, the Court intended the test to be whether the claimed
invention has “distinctive name, character, and use.” 171 Myriad
was correct that Chakrabarty did not establish the “markedly
different characteristics” analysis as a test for determining
whether a claimed invention is sufficiently altered to avoid the
three exceptions. But Chakrabarty did not indicate that the
“distinctive name, character, and use” analysis was to be the
sole test; its discussion on the matter was quite specific to the
facts of that case and did not establish a particular test. 172
Therefore, a proper analysis would treat the “markedly
different characteristics” analysis, the “distinctive name,
character, and use” analysis, and all other reasoning expressed
by Chakrabarty equally.
When determining whether the claimed invention fits
under one of the three exceptions, the Chakrabarty court posed
the question of whether the claim is to “a hitherto unknown
natural phenomenon” or a “nonnaturally occurring
manufacture or composition of matter.” 173 The court mentioned
the following criteria as guidance: (1) whether the claim is to “a
product of human ingenuity having a distinctive name,
characteristic, and use,” 174 (2) whether the claim is to
something “with markedly different characteristics from any
found in nature and one having the potential for significant
utility,” and (3) whether the claim is to “nature’s own
handiwork or [the patentee’s].” 175 While Chakrabarty did not
establish any of these criteria as an exclusive test for patent
eligibility, because Myriad’s composition-of-matter claims are
supported by all three characteristics, the Chakrabarty
analysis is sufficient.
The opinion suggests that Myriad’s composition claims
point to natural phenomena that occur naturally absent human
intervention, because both Myriad’s claimed BRCA1 and
169. Id. at 223 (quoting Diamond v. Chakrabarty, 447 U.S. 303, 310
(1980)).
170. Brief for Appellants, supra note 162, at 41–42.
171. Id. at 42 (quoting Chakrabarty, 447 U.S. at 309–10).
172. See Chakrabarty, 447 U.S. 309–10.
173. Id. at 309.
174. Id. at 309–10 (quotation omitted).
175. Id. at 310.
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BRCA2 genes and natural BRCA1 and BRCA2 genes have the
same informational encoding capacity and purpose. 176 As
Myriad notes, the court erred in focusing on such a narrow
aspect of Myriad’s claims, 177 because claims must be considered
as a whole when determining patent eligibility. 178 Myriad
essentially argues that their inventions were held patent
ineligible because of general genetic concept, when they should
have been held patent eligible because of the changes Myriad
made to the DNA. 179 “[I]t is inappropriate to dissect the claims
into old and new elements and then to ignore the presence of
the old elements in the analysis.” 180 When Myriad’s claims are
viewed more thoroughly, they are patent eligible.
i. Myriad’s Claims Are the Product of Human Ingenuity
Having Distinctive Characteristics and Uses
Myriad admits that its claimed genes and the natural
genes are codes for the same exact proteins. 181 This concession
is not surprising, because the entire purpose of sequencing and
isolating the BRCA1 and BRCA2 genes was to discover the
cancer-related proteins for which they code. 182 However, this
code serves different purposes in the claimed and in natural
DNA. The purpose of the sequence of genes in natural DNA is
to make the production of proteins possible. 183 The purpose of
the sequence of genes in Myriad’s claimed isolated DNA is to
identify mutations in BRCA1 and BRCA2 genes. 184 The
structural differences between the two types of DNA serve this
176. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office
(Myriad), 702 F. Supp. 2d 181, 229 (S.D.N.Y. 2010).
177. Brief for the Appellants, supra note 162, at 51.
178. Diamond v. Diehr, 450 U.S. 175, 188 (1981).
179. Brief for the Appellants, supra note 162, at 51.
180. Id.
181. Myriad, 702 F. Supp. 2d at 231.
182. Id. at 201.
183. See SOLOMON, ET AL., supra note 2 at 261, 278. While Myriad’s
isolated DNA do not serve this purpose, some isolated DNAs could be useful
for laboratory protein production. In this case, the use would still be different
from that of natural DNA. Natural DNA produces only small amounts of
protein for use in the body, while isolated DNA could be used to produce
extremely large amounts of protein for sale or other purposes. Brief of Amici
Curiae Rosetta Genomics, Ltd., et al. as Amici Curiae supporting Appellants,
at 23, Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 702 (No. 20101406) (Fed. Cir. filed June 16, 2010).
184. Myriad, 702 F. Supp. 2d at 203.
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difference in purpose: as Myriad puts it, natural “DNA is
useless for the diagnostic and detection applications for which
the isolated molecules may be utilized.” 185 To begin with,
isolated DNA is not found in chromosomal form, and thus it is
never coiled, twisted, or surrounded by proteins that make it
difficult or impossible to compare the sequence of one gene with
that of another. 186 That the claimed DNA is isolated suggests
that it is also separated from the thousands of other genes on
the chromosome, making the DNA far less unwieldy. 187
Further, isolated DNA is without extra sequences unimportant
to gene comparison, such as sequences that serve to regulate
cellular processes and noncoding introns. 188
These distinctions between native and isolated DNA are
not a product of nature’s efforts. Indeed, the Myriad court
admitted that the differences are a direct result of Myriad’s
effort and ingenuity. 189 This is necessarily so, because the
human body can neither isolate DNA nor cDNA, such that
neither can regularly occur in nature and both are the result of
genetic manipulation. 190 The changes Myriad has made to the
DNA “permit the direct yoking of natural processes for
mankind’s purposes.” 191 Clearly, Myriad’s claimed DNA is the
product of human ingenuity having distinctive characteristics,
uses, and (if the scientific community so chooses) names from
natural DNA. 192
ii. The Distinctions Between Myriad’s DNA and Natural DNA
are Marked, and Create the Potential for Significant Utility 193
Chakrabarty gave no guidance for determining if a claimed

185. Brief for the Appellants, supra note 162, at 51.
186. Myriad, 702 F. Supp. 2d at 195–96.
187. See Rosetta Genomics, supra note 183 at 23 (describing chromosomes
as large structures with numerous genes and DNA sequences).
188. Id. at 24.
189. Myriad, 702 F. Supp. 2d at 202.
190. Rosetta Genomics, supra note 183 at 22–23; Brief for the United
States as Amicus Curiae in Support of Neither Party at 15, Ass’n for
Molecular Pathology v. Myriad Genetics, Inc., No. 2010-1406 (Fed. Cir. briefs
submitted Oct. 22, 2010). The U.S. Department of Justice notes in its amicus
brief that cDNAs do sometimes occur in nature, in viruses, for example, but
not in humans.
191. See Brief for the United States, supra note 190, at 16.
192. See Rosetta Genomics, supra note 183, at 22–23.
193. The utility for diagnostic tests, made possible by isolated DNA is
discussed in the public policy section below. See infra Part IV.C..
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invention is “markedly different.” 194 However, the way
Chakrabarty made the determination is instructive. The
patentee had invented a biologically engineered bacterium by
inserting new DNA sequences into the bacterium’s natural
DNA. 195 The claimed bacterium, as a result of the patentee’s
engineering, was able to degrade oil more efficiently, and thus
was useful in treating oil spills. 196 Previously, multiple bacteria
were required to degrade oil, but the claimed bacterium was
able to do the same work alone. 197 Therefore, in Chakrabarty,
an organism’s DNA was altered to allow it to perform a task
more efficiently. The inventive difference between the invention
and its natural counterpart was the change in DNA. Similarly,
the inventive difference (among others) between Myriad’s
invention and its natural counterpart is a change in DNA. 198
While the sequences encoding the gene remain in both Myriad’s
invention and its natural counterpart, the amount of DNA and
other substances removed cause a marked difference. 199
Further, the operative difference between the Chakrabarty
invention and its natural counterpart is an improvement in
performance. 200 However, the operative difference between
Myriad’s invention and its natural counterpart is an entirely
new use that would have been impossible without the
invention. 201 Myriad’s is the only test available to diagnose
hereditary breast cancer. 202 Therefore, there are marked
operative differences between Myriad’s DNA and natural DNA.
iii. Myriad’s Claims are to Myriad’s Handiwork, Not Nature’s
As discussed, the new use resulting from Myriad’s claimed
invention developed from Myriad’s ingenuity. 203 For example,

194. Diamond v. Chakrabarty, 447 U.S. 303, 310 (1980).
195. Id. at 305.
196. Id. at 305 n.2.
197. Id.
198. Brief for the Appellants, supra note 162 at 50–51. The difference
between this case and Chakrabarty is that here DNA was removed, instead of
added.
199. See supra notes 185–188 and accompanying text.
200. Chakrabarty, 447 U.S. at 305 n.2.
201. Brief for the Appellants, supra note 162 at 50–51.
202. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office
(Myriad), 702 F. Supp. 2d 181, 206 (S.D.N.Y. 2010).
203. Id. at 202.
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cDNA, is not found naturally in humans 204 and there is no
natural method for isolation of DNA. 205 Because the differences
between Myriad’s invention and its natural counterpart result
largely from the isolation of the DNA and its change to cDNA,
the differences cannot be said to be nature’s handiwork. 206
Further, because these differences are the direct causes of the
usefulness of Myriad’s claimed invention, 207 it follows that the
invention is not nature’s handiwork.
The Myriad opinion mentions that at least one of Myriad’s
claims can be read so broadly that it encompasses the DNA
that it exists in the human body and that Myriad is therefore
claiming nature’s handiwork. 208 But this is not an appropriate
reading of the claims. A patent’s claims must be read in light of
all other claims, the specification, and the invention as a
whole. 209 Given that the clear purpose of Myriad’s invention is
to diagnose likelihood of hereditary breast cancer and that
natural DNA is useless to that end, it is nonsensical and
against patent regulations to read any of Myriad’s claim in a
way that would include natural DNA as it exists in humans. 210
4. Myriad’s Genes Are Not Patent Ineligible Because They Are
Purifications of a Natural Substance
Amici (notably, the United States Department of Justice)
argue that genes cannot be patented as compositions of matter
due to the longstanding exception to § 101 that purification of
something unpatentable does not result in a patent eligible
invention. 211 In Cochrane, the patentee originally attempted to
patent both a process for synthesizing a dye that was
previously available only by extraction from a plant and the
dye itself. 212 The synthetic dye was found not patent eligible
204. See United States, supra note 190 at 15.
205. Rosetta Genomics, supra note 183 at 22.
206. See supra notes 189–191 and accompanying text.
207. See supra notes 184–186 and accompanying text.
208. Myriad, 702 F. Supp. 2d at 230.
209. See 37 C.F.R. § 1.104 (2009) (establishing that examination of a patent
must be a thorough study of the whole application); 35 U.S.C. § 112 (2006)
(establishing that the application’s specification provides context for the
invention and manner of use of the invention); supra notes 178, 180 and
accompanying text.
210. 37 C.F.R. § 1.104 (2010); supra notes 178, 180 and accompanying text.
211. Cochrane v. Badische Anilin & Soda Fabrik, 111 U.S. 293, 311–12
(1884).
212. Id.
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because it was not a new article. 213 However, there is a
longstanding exception to the purification exclusion: purified
articles that differ from their previous counterparts not only in
degree of purity but also in kind adopt a new use are patent
eligible. 214 In re Merz invalidated a patent for a dye for the
same reasons given in Cochrane, 215 but noted in dicta that if
the dye had been so much purer that it differed in kind and was
useful in a new way from the previous dye, it would have been
patentable. 216
It is undisputed that the isolation and purification of the
BRCA1 and 2 genes from their natural environment has
created articles different in kind from their natural
counterparts. 217 While genes purified to a lesser extent than
Myriad’s genes may still be useful to produce proteins, they
would be useless for diagnostic tests. 218 Only Myriad’s genes,
once purified, are useful for this application. 219 Therefore, they
fall under the “different in kind” exception, and are not patent
ineligible because they are purifications.
5. Myriad’s Genes Are Not Patent Ineligible Under Funk Bros.
The Myriad opinion relied to a large extent on Funk Bros.
to establish that Myriad’s genes are patent ineligible under §
101. 220 Funk Bros. held that combining three types of bacteria
into a culture that efficiently allows plants to fix nitrogen from
the atmosphere did not result in a patentable invention. 221
Because it was well known that these species of bacteria
allowed plants to fix nitrogen and that certain species of the
bacteria inhibited the fixing effects of other species, it was a
clear next step to combine only bacteria that do not inhibit each
other when composing plant additives. 222 This analysis is

213. Id.
214. In re Merz, 97 F.2d 599, 601 (C.C.P.A. 1938).
215. Id.
216. Id.
217. See supra notes Part IV.A.3.i.
218. See supra notes Part IV.A.3.ii.
219. See supra notes Part IV.A.3.ii.
220. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office
(Myriad), 702 F. Supp. 2d 181, 232 (S.D.N.Y. 2010).
221. Funk Bros. Seed Co. v. Kalo Inoculant Co. (Funk Bros.), 333 U.S. 127,
129–30, 131–32 (1948).
222. Id.
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known today as the obviousness analysis from § 103. 223
However, Funk Bros. was decided just before the Patent Act of
1952, when the obviousness rejection from Hotchkiss was so
named and codified under § 103. 224 Therefore, Funk Bros. is not
applicable to modern cases of patent eligibility under § 101, but
under § 103, 225 and thus Myriad’s claims cannot be held to be
patent ineligible under § 101 due to Funk Bros. Even if the
obviousness standard applied to patent eligibility in this case,
Myriad’s claims would still not be ineligible.
6. Deference to USPTO Determination, Precedent, and
Congressional Intent Support Patentability of Genes as
Compositions of Matter
The Supreme Court has deferred to the longstanding
judgment of the patent office in its reading of statutes
governing patent eligibility. 226 Given the over 40,000 patents
on genes issued by the USPTO—and the lack of any action to
the contrary by Congress—a holding that genes are not patenteligible would violate the precedent of deference to the
longstanding judgment of the USPTO. 227 Further review of the
precedents shows that the Federal Circuit, which, due to their
expertise in the field, handles all appeals from the Board of
Patent Appeals and Interferences, 228 has a history of assuming

223. 35 U.S.C § 103 (2006). See also KSR Int’l Co. v. Teleflex Inc., 550 U.S.
398, 406 (2007) (explaining the test for obviousness under § 103).
224. Funk Bros., 333 U.S. at 127; KSR, 550 U.S. at 406 (stating that the
analysis and language from § 103 in the 1952 Patent Act establishing §§ 100–
03 was taken from Hotchkiss v. Greenwood); Hotchkiss v. Greenwood, 52 U.S.
(11 How.) 248, 267 (1851).
225. Brief for Alnylam Pharmaceuticals, Inc. as Amicus Curiae Supporting
Petitioners at 13-14, Ass’n for Molecular Pathology v. Myriad Genetics, Inc.,
No. 2010-1406 (Fed. Cir. Oct. 22, 2010).
226. See, e.g., J.E.M. AG Supply v. Pioneer Hi-Bred Int’l, 534 U.S. 124,
144–45 (2001) (holding that, because the USPTO had found multiple plant
inventions patent eligible under § 101, and because Congress had not
expressed disapproval of such findings, a holding against the USPTO’s
judgment on patent eligibility would be improper).
227. Rosetta Genomics, supra note 183, at 14; Genomic Research and
Accessibility Act, H.R. 977, 110th Cong. (2007) [hereinafter GRAA] (this bill
never
became
law),
available
at
http://www.govtrack.us/congress/billtext.xpd?bill=h110-977.
228. Court Jurisdiction, UNITED STATES COURT OF APPEALS FOR THE
FEDERAL
CIRCUIT,
http://www.cafc.uscourts.gov/index.php?option=com_content&view=article&id
=144&Itemid=27 (last visited Nov. 22, 2010). Given the fact that this court
was formed from the United States Court of Customs and Patent Appeals and

838

MINN. J. L. SCI. & TECH.

[Vol. 12:2

genes to be patent eligible. 229 Finally, the fact that Congress
explicitly refused to bar gene patent eligibility under § 101 in
the Genomic Research and Accessibility Act, 230 especially in
light of growing controversy on the issue, demonstrates the
congressional intent that genes remain eligible for patenting.
B. MYRIAD’S METHOD CLAIMS ARE PATENT ELIGIBLE UNDER §
101
1. The “Machine-or-Transformation” Test Is No Longer
Dispositive
The Myriad opinion’s invalidation of Myriad’s method
claims relied heavily on the Federal Circuit’s decision in In re
Bilski. 231 But the district court’s view that Myriad’s method is
not tied to a particular machine or apparatus and does not
perform sufficient transformation is no longer dispositive since
the Supreme Court’s disapproval of In re Bilski, on the ground
that the “machine-or-transformation” test was not meant to be
a binding test. 232 Instead, method patents which otherwise
comply with statutory provisions are patent eligible unless they
are merely abstract ideas. 233
After the Supreme Court’s Bilski decision, the machine-ortransformation analysis remains important as a “clue” in
determining patent eligibility. 234 Myriad’s method claims are
made more patent eligible, rather than less, by this analysis.
There are multiple steps that a court could identify as
transformative; a patient’s blood must first be treated and the
DNA from the blood must be isolated and sequenced. 235 This is
especially determinative, as the Federal Circuit has recently
held similar treatment of blood to be transformative in
Prometheus Laboratories, Inc. v. Mayo Collaborative

the deference the Supreme Court gives to the expertise of the Board of Patent
Appeals and Interferences, this court can be assumed to have some expertise
in patents. See J.E.M. 534 U.S. at 144–45.
229. See, e.g., Amgen, Inc. v. Chugai Pharm. Co., 927 F.2d 1200, 1219 (Fed.
Cir. 1991).
230. See GRAA, supra note 227.
231. Supra notes 137–144 and accompanying text.
232. Bilski v. Kappos, 130 S. Ct. 3218, 3226 (2010).
233. See id. at 3229–30.
234. Id. at 3227.
235. Brief for the Appellants, supra note 162 at 55.

2011]

MEDICINE AND PATENT LAW

839

Services. 236 The machine-or-transformation analysis, therefore,
strengthens the patent eligibility of Myriad’s method claims.
2. Myriad’s Method Claims Are Not Abstract Ideas
The Myriad opinion suggests that Myriad’s method claims
are patent ineligible because they are related not to any
particular method of analysis, but instead to the mental
process of “comparing” sequences. 237 However, Myriad’s
method claims represent far more intricate processes than
simply looking at a list of nucleotides side-by-side. To begin,
isolating the correct sequences of a person’s DNA requires
several non-abstract steps. 238 Further, any differences between
a person’s DNA and Myriad’s gene will need to be examined to
determine whether those mutations are of any effect. Because
this requires extensive analysis, 239 Myriad had to develop
several tests to identify different types of mutations. 240
Myriad’s tests are far from abstract ideas and are therefore
patent eligible.
C. POLICY RAMIFICATIONS OF INVALIDATING GENE PATENTS
The Myriad opinion’s sudden invalidation of patents on
human genes, if supported by higher courts and the USPTO,
will have tremendous consequences, 241 and it has already
unsettled much of the patent community. 242 To begin, the

236. Prometheus Labs., Inc. v. Mayo Collaborative Servs., 628 F.3d 1347,
1356 (2010).
237. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office
(Myriad), 702 F. Supp. 2d 181, 233 (S.D.N.Y. 2010).
238. Brief for the Appellants, supra note 162, at 55.
239. See Myriad, 702 F. Supp. 2d at 195 (explaining that different types of
mutations in a person’s DNA will have different effects); id. at 195 n.5
(explaining that extensive analysis is required to determine what effect each
mutation will have); supra notes 42–44 and accompanying text (explaining
that many mutations will have no effect).
240. Myriad, 702 F. Supp. 2d at 203.
241. Dennis Crouch referred to the decision as “a powerful move.” Dennis
Crouch, Court: Essentially All Gene Patents Are Invalid, PATENTLY-O (Mar.
30,
2010,
7:17
AM),
http://www.patentlyo.com/patent/2010/03/courtessentially-all-gene-patents-are-invalid.html. The title of this blog entry
emphasizes the far-reaching potential this decision could have.
242. Paul M. Janicke, Guest Post: An Interesting Preview of Myriad?,
(Sept.
26,
2010,
10:29
PM),
PATENTLY-O
http://www.patentlyo.com/patent/2010/09/guest-post-an-interesting-previewof-myriad.html.
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USPTO has granted patents to over 40,000 genes, 243 over
ninety-nine percent of which have never been challenged.
Moreover, only a fraction of the remaining one percent were
challenged because of their patent eligibility or ineligibility. 244
The purpose of patent law is to “promote the Progress of
Science and the useful Arts.” 245 The patent system promotes
science by giving inventors an incentive to develop marketable
inventions and technologies. 246 However, the public at large is
benefitted greatly by the patent system as well for at least two
reasons: (1) many useful inventions that are patented are
marketed and sold to consumers, who benefit from the
invention’s availability; and (2) in order to get a patent, an
inventor must describe (enable) the invention in the published
patent application in a way that would allow another person to
make and use the invention. 247 This enablement allows others
to use the patent application to discover new improvements to
the invention or technology, and patent law incentivizes
improvements on known inventions and technology, further
increasing the public’s benefit from the original patent. 248
Applying these concepts to the medical field, it follows that
giving the benefits of patent protection to the inventors of
medical technologies will increase the amount of benefit the
public at large receives from the medical technology field. 249
However, there is some dispute as to whether the incentive to
develop medical technologies such as Myriad’s gene sequences
and diagnostic tests is greatly increased by the benefits of
patenting those technologies. 250 The research that leads to
243. Rosetta Genomics, supra note 183, at 14.
244. Id. at 29-30. See also Crouch, supra note 241 (describing Judge
Sweet’s Myriad decision as against “standard thoughts on patentability.”).
245. U.S. CONST. art. 1, § 8, cl. 8.
246. See id. (securing, “for limited [t]imes,” the patent holder’s exclusive
right to profit from those inventions and technologies).
247. 35 U.S.C. § 112 (2006).
248. See 35 U.S.C. § 101 (2006)
(granting patent eligibility to
improvements upon previous patented inventions).
249. See Brian Murphy & Daniel Murphy, Bilski’s “Machine-orTransformation” Test: Uncertain Prognosis for Diagnostic Methods and
Personalized Medicine Patents, 20 FORDHAM INTELL. PROP. MEDIA & ENT. L.J.
755, 760 (2010) (suggesting that the incentive provided by a broad patent
eligibility test is especially important in the fields of medicine and genetic
diagnostics).
250. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office
(Myriad), 702 F. Supp. 2d 181, 210 (S.D.N.Y. 2010).

2011]

MEDICINE AND PATENT LAW

841

many of these technologies receives federal funding in the form
of grants or public university research. 251 But further analysis
indicates that medical technologies are not beyond the effects of
patent incentivization.
1. Patent Protection Incentives Are Important to University
and Private Research
Although their research is partially supported by public
funds, universities are able to profit from that research, 252 and,
through patents, to prevent others from competing with
them. 253 Therefore, while the costs incurred by a university in
developing patentable and profitable technologies may be more
likely to be subsidized than those incurred by a private
organization, universities’ ability to reap benefits from the
patent system in the same way that private organizations do
suggests that they are not impervious to the incentives it
provides. 254 Even assuming that university research efforts are
largely unaffected by the incentives of the patent system does
not defeat the importance of the patent system to their
research, for, as their research is released into the public
domain, private entities are free to develop improvements upon
that research, creating more marketable technologies. 255
Without the incentives of the patent system, those private
entities would be unable to recoup their research costs and
would not improve university research in the public domain. 256
It is true that, even absent research assistance from public
universities, private entities are often given research subsidies
from public funds. 257 But those funds help to research only the
basic technologies of a patentable product; the cost of

251. See, e.g., id. (revealing that research for 63% of patents on gene
sequences was partially funded by the government). Also relevant, is the fact
that a public university is part owner of Myriad’s patents. Id. at 189–90.
252. See, e.g., Joe Kays & Arline Phillips-Han, Gatorade: The Idea That
Launched an Industry, EXPLORE RESEARCH AT THE UNIVERSITY OF FLORIDA
(Spring
2003),
http://www.research.ufl.edu/publications/explore/v08n1/gatorade.html.
253. Property Rights: The Granting of Patents on Human Genes Has so far
not Been the Disaster it Was Predicted To Be, 458 NATURE 386, 386 (2009).
254. It is true, however, that universities may do research that is never
expected to result in a patentable product, but is simply released into the
public.
255. 35 U.S.C. 101 (2006).
256. See Myriad, 702 F. Supp. 2d at 211.
257. See id. at 210.
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developing a commercially profitable application of that
product is far greater and dwarfs the funding typically given to
private research. 258 Therefore, it is likely that, without the
incentives of patent protection, the research assisted by federal
subsidies will stop well short of anything useful to the public,
because the costs would be prohibitive.
2. The Public is Best Served by Maintaining the Incentives of
Patent Protection to Medical Inventors
Advanced medical tests, especially diagnostic DNA tests,
can be very expensive. 259 If the provider of a medical procedure
is given a partial monopoly by patent protection, that provider
will have more freedom in setting the price of the procedure. 260
Therefore, when several firms are providing a medical
procedure, consumers will pay less for the procedure than if
there were only one provider. Thus, if Myriad were not allowed
to gain patent protection on its gene and diagnostic tests, those
tests would be available to consumers at lower prices.
The benefit of allowing patents for genes and resulting
diagnostic tests is not much more complicated. If Myriad had
known before sequencing the BRCA1 and BRCA2 genes that it
would not be granted patents on them, it would not have
performed the research. 261 Retroactively taking patent
protection away from a company that has already performed
research and prepared the resulting genetic test will remove its
monopoly of diagnostic testing and create competition to drive

258. See id. at 211.
259. Amy Dockser Marcus, Obsessed With Genes (Not Jeans), This Teen
Analyzes Family DNA, WALL ST. J., Oct. 1, 2010, at A1.
260. Harold Demsetz, Why Regulate Utilities?, 11 J.L. & ECON. 55, 56
(1968).
261. Murphy, supra note 249, at 764. The costs of developing genetic tests
can be hundreds of millions of dollars, while Myriad was only reported to have
been given 22 million dollars in funding. Id. at 760–61; Ass’n for Molecular
Pathology v. Myriad Genetics Inc. 09 Civ. 4515 at 49 (S.D.N.Y. 2010),
available
at
http://www.aclu.org/files/assets/2010-3-29-AMPvUSPTOOpinion.pdf. A mistake was made in the Federal Supplement version of this
case, misrepresenting the amount that Myriad received in funding. The
original court opinion has been cited. Compare Ass’n for Molecular Pathology
v. Myriad Genetics Inc. 09 Civ. 4515 at 49 (S.D.N.Y. 2010), available at
http://www.aclu.org/files/assets/2010-3-29-AMPvUSPTO-Opinion.pdf (stating
that Myriad had been given 22 million dollars in funding) with Myriad, 702 F.
Supp. 2d at 201 (stating that Myriad had been given 122 million dollars in
funding).

2011]

MEDICINE AND PATENT LAW

843

the cost of the tests down, but may prevent the development of
future genetic tests for other cancers, or improved genetic tests
for breast cancer. The long-term future consequences of
removing patent protection for genetic tests can be illustrated
by analyzing what would have happened if patent protection
had never been offered for genes. Myriad would have been less
willing to spend the vast amounts of money necessary to
discover the sequences BRCA1 and BRCA2 genes and develop a
marketable genetic test. 262 This would prevent over 70,000
women per year from being able to receive the BRCA1 and/or
BRCA2 analysis. 263 Moreover, without the patent incentive,
many genes 264 with important medical implications would
never have been sequenced, and thus thousands of patients
would be without the benefit of decades of medical research. 265
For example, currently 250,000 Americans suffer from a
hereditary genetic neurological disease known as Huntington’s
disease. 266 Huntington’s disease causes neural degeneration, at
first inhibiting an individual’s fine motor skills and eventually
the ability to talk, reason, and remember. 267 Huntington’s
disease is completely linked to the gene; if a person has the
gene, he or she will develop the disease, and die within twenty
or fewer years. 268 Most individuals do not develop symptoms of
the disease until they are between thirty and fifty years of
age—often after having children to whom they had a fifty
percent chance of passing on the disease. 269 The importance of
genetic testing to families with a history of Huntington’s
262. See Rosetta Genomics, supra note 183, at 7 (suggesting that without
patent protection, many gene based products will never reach the public).
263. Myriad charges approximately 3,000 dollars per test, and performed
220,000,000 dollars worth of tests in 2008. Therefore, Myriad performed over
70,000 tests in 2008. See Myriad, 702 F. Supp. 2d at 203.
264. The potential number of genes patents affected could be quite high, as
40,000 genes have been patented. See Editorial: Property Rights: The Granting
of Patents on Human Genes Has So Far Not Been the Disaster It Was Predicted
to Be, 458 NATURE 386, 386 (2009).
265. See, e.g., Marsha L. Miller, HD Research - Past and Future,
HUNTINGTON’S
DISEASE
SOCIETY
OF
AMERICA,
http://www.hdsa.org/research/past-and-future.html (last visited June 11, 2011)
(reporting that, since the discovery of the Huntington’s gene in 1993, an
explosion of research has been performed regarding Huntington’s disease).
266. What is HD, HUNTINGTON’S DISEASE SOCIETY OF AMERICA,
http://www.hdsa.org/about/our-mission/what-is-hd.html (last visited June 11,
2011).
267. Id.
268. Id.
269. Id.
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disease is clear, but without gene patent eligibility, the testing
would likely not be available today. 270
Applying this illustration to future research elucidates the
effects that stripping patent eligibility from genes may hinder
genetic research and slow the development of medical
innovation. This result would be devastating to future
generations suffering from currently incurable genetic diseases
or genetically linked diseases that cannot currently be
diagnosed because the genes are undiscovered. Without patent
protection, further research on both unidentified and identified
genes and their effects would not be incentivized, potentially
foreclosing treatments and cures for currently untreatable or
incurable diseases such as breast cancer and Huntington’s
disease. 271
On the other hand, it has been suggested that allowing
patent protection for genes will allow patent holders to prevent
further research on those genes, thus stunting genetic research
more than a lack of incentive would. 272 In reality this is highly
unlikely; patent law is specifically designed to encourage
improvements and innovations of currently patented inventions
and technology. 273 While some scientists may believe that gene
patents would restrict their research, 274 those scientists appear
to be over-cautious because scientists being blocked from
research is a nonissue. 275 Even Myriad’s patents, the
controversy of which is made clear by the existence of this case,
has left research open to the public and has had almost no
effect on BRCA1 and BRCA2 research. 276 Indeed, since
Myriad’s patents were granted, over 18,000 scientists have
270. Rosetta Genomics, supra note 183, at 7.
271. Id.; see also Murphy & Murphy, supra note 249, at 764.
272. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office
(Myriad), 702 F. Supp. 2d 181, 208 (S.D.N.Y. 2010)..
273. 35 U.S.C. § 101 (2006) (establishing that discoverers of improvements
on previous inventions may patent those improvements). But see 35 U.S.C. §
271 (2006) (establishing that patent holders can prevent the making, using or
selling of their inventions).
274. Myriad, F. Supp. 2d at 208.
275. See Editorial, supra note 264, at 386. The editorial suggests that, even
in cases where a scientist’s research could be hindered, legal workarounds are
quite simple.
276. DEP’T OF HEALTH & HUMAN SERVS., REPORT OF THE SECRETARY’S
ADVISORY COMMITTEE ON GENETICS, HEALTH, AND SOCIETY: GENE PATENTS
AND LICENSING PRACTICES AND THEIR IMPACT ON PATIENT ACCESS TO
GENETIC TESTS at 75 (2010).
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conducted research on the BRCA1 and BRCA2 patents,
resulting in over 7000 papers. 277 It appears, then, that
hindrance of future genetic research is not a reasonable policy
argument against patenting genes.
D. MYRIAD’S METHOD CLAIMS MAY NOT BE VALID UNDER §102
OR §103
Though it is clear public policy favors patenting of genes
and the diagnostic tests based on those genes, and even if
Myriad’s method claims are held to be patent eligible under §
101, affirming the district court’s invalidation of the claims on
different grounds could be proper for novelty’s or
nonobviousness’ sake. 278
1. Myriad’s Diagnostic Methods May Be Considered Not Novel
As the Myriad opinion notes, all methods employed by
Myriad in its diagnostic claims have been in the public domain
for some time 279 and are known and performed by scientists
every day. 280 Further, the processes used in Myriad’s diagnostic
tests (isolating and sequencing DNA) are the same processes
performed when locating and sequencing a gene, the necessary
steps for patenting a gene. Therefore, these steps have been
well known since at least 1990, the start of the Human Genome
Project. 281 Given that Myriad’s first patent application was not
until 1994, 282 this creates a large novelty obstacle to holding
Myriad’s method claims valid. 283 That these particular
diagnostic procedures have never been performed before with
277. Rosetta Genomics, supra note 183, at 15. Of particular interest is the
fact that several of the plaintiffs complaining that gene patents block genetic
research have themselves published over 48 papers on the very genes Myriad
has patented. Id.
278. 35 U.S.C. §§ 102–03 (2006). If Myriad’s process claims are found
invalid, a further argument could be made against the composition of matter
claims: without any way to prosper from the genes, the genes would not be
useful aside from their benefits to the public domain. As usefulness is a
condition of patent eligibility, this may create a bar to the composition of
matter claims. 35 U.S.C. § 101 (2006). This line of reasoning is beyond the
scope of this comment, though could be addressed in further publications.
279. Myriad, 702 F. Supp. 2d at 200.
280. Id.
281. Id. at 193.
282. Id. at 212 n.26.
283. See 35 U.S.C. § 102 (establishing that any procedure that was in use
by the public more than one year before the patent’s application date is not
novel).
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this particular gene may influence the reviewing court,
especially given the public policy interests and the deference to
USPTO determinations. 284 Whatever the court’s determination
on the issue, an opinion validating or invalidating Myriad’s
method claims should address this issue.
2. Myriad’s Diagnostic Methods and Compositions of Matter
May Be Considered Obvious
Even if a court does not invalidate Myriad’s diagnostic
methods for novelty reasons, the obstacle of obviousness will
remain for both the diagnostic methods and the compositions of
matter. Arguments are strong for both a finding of obviousness
and nonobviousness. Under § 103, an invention is obvious when
a person of ordinary skill in the art would have known how to
produce and patent the article under scrutiny as of the date of
the invention. 285 The determination of whether an invention is
obvious may involve consideration of the commercial success of
the patented article, “[the] long felt but unsolved needs, failure
of others, etc.” 286 Because the processes used in Myriad’s
diagnostic tests are used by scientists every day, 287 it is
reasonable that they would be obvious to someone “of ordinary
skill in the [field].” 288
However, it is also reasonable that if the diagnostic
methods escape the novelty rejection because the methods had
never been applied to this particular gene, the court may also
overlook an obviousness rejection based on the same argument.
This is especially true because the knowledge that makes it
obvious to apply the method to this gene is the gene’s sequence,
which was not known by those of ordinary skill in the art until
the patent application was published. Patent law indeed holds
an obviousness exception when a biotechnology method, as
here, is applied to a composition of matter patented at the same
time, but the methods listed in the statute do not seem to
encompass diagnostic testing. 289
This leads to Myriad’s composition of matter claims.
284. Supra notes 259–268 and accompanying text; supra notes 226–227
and accompanying text.
285. See Graham v. John Deere Co., 383 U.S. 1, 17–18 (1966).
286. Id.
287. Myriad, 702 F. Supp. 2d at 200.
288. 35 U.S.C. § 103 (2006).
289. 35 U.S.C. § 103(b).
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Because Myriad’s claims resulted in an invention with great
commercial success, 290 and because many others attempted but
failed to develop the same invention, 291 there some merit to the
argument that Myriad’s invention was not obvious. 292 However,
many of ordinary skill in Myriad’s field realized the need for
the invention 293 and there are only so many possible sequences
the BRCA1 and BRCA2 genes could have expressed, therefore
the composition of matter patents may be found obvious to
try. 294 On the other hand, while there is a finite number of
possible sequences for the BRCA1 and BRCA2 genes, one who
is trying to discover a gene can assume that it is thousands of
base pairs long, 295 and because each position could be held one
of four nucleotides, the number of possible sequences for any
one gene is enormous. 296 Therefore, a court could also find that,
though the prior art gives guidance as to the form of the
invention, the only way to discover the invention is to throw
darts at a board composed of all possibilities, and therefore
being obvious to try would not give rise to obviousness. 297
The Federal Circuit considered this argument in Kubin,
and found that determining a gene sequence was indeed
obvious because it was obvious to try. 298 However, in that case,
the applicant started off knowing the sequence of the one
protein for which the gene encoded, from which they could work
backwards to determine the sequence of the gene. 299 Being able
to work backwards from an expressed gene product to the gene
would be a far more predictable, and profoundly less similar to
throwing darts at a board of composition of matter possibilities
290. Myriad, 702 F. Supp. 2d at 203 (stating that Myriad made over 200
million dollars in revenue from their diagnostic tests in 2008).
291. Id. at 201–02 (stating that multiple other groups were attempting to
develop the claimed invention at issue, but that they did not succeed before
Myriad).
292. See Graham v. John Deere Co., 383 U.S. 1, 17–18 (1966) (suggesting
that the long-felt need for an intention and the failed attempts of others may
be useful in the determination of obviousness).
293. See Myriad, 702 F. Supp. 2d at 201 (describing the funds and efforts
that several research teams across the world put into being the first to
discover the sequence of the BRCA1 gene).
294. Supra notes 110–111 and accompanying text.
295. See Myriad, 702 F. Supp. 2d at 194 (stating that a typical gene is
thousands of nucleotides long).
296. Supra note 27 and accompanying text.
297. In re Kubin, 561 F.3d 1351, 1359 (Fed. Cir. 2009).
298. Id. at 1361.
299. Id. at 1360.
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than would sequencing a gene from scratch. 300 Therefore, it
appears that the obviousness of Myriad’s composition of matter
claim could be resolved in either direction.
V. CONCLUSION
It is unwise to blithely remove patent eligibility from fields
in which incentives for innovation have a dramatically positive
effect on the population as a whole. Patent law was established
to incentivize inventions that are useful to the public, while
still allowing fair access to innovations. Because the public
benefit resulting from incentivizing gene patents far outweighs
the potential for public loss, it is in the country’s best interest
to structure and interpret patent law to find genes and
methods employing them patent eligible.
Unfortunately, patenting genes is a controversial issue
right now, and the courts cannot decide patent eligibility on the
basis of public policy alone. Patent law does allow for an
interpretation that would find genes and the methods
employing them patent eligible, but those methods are likely to
encounter novelty and obviousness rejections that they may be
unable to overcome. Currently, patent law does not provide a
clear solution.
This Comment suggests that the Court of Appeals for the
Federal Circuit should reverse the district court’s decision in
Myriad on all counts. However, it is the stance of this Comment
that patent law does not provide enough clarity for gene
patents, especially where methods are concerned. Therefore,
any decision made by this court and the Supreme Court on
gene patent eligibility should include an appeal to Congress to
amend the current patent laws to provide more and clearer
protection to gene patents in terms of patent eligibility, novelty,
and obviousness.
The Association for Molecular Pathology, and other
research organizations should also appeal to Congress.
Although Congress has shown unwillingness to outlaw gene
patents, researchers may be placated by a compromise that
would protect their interests. Mandatory licensing of all gene
patents to not-for-profit researchers, for example, would allow
300. See id. (suggesting that those skilled in the art would consider
working backwards from a known protein sequence to determine the gene
coding for it to be “profoundly predictable.”).
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public research into genes, while protecting the genetic
diagnosis industry. Whatever the result in the Myriad appeal,
the continuing market for patents in genes and genetic
diagnostic tests, and the medical advances that could follow
will depend on a system of patent law more appropriate for the
advancing field of genetics.

